Are janus kinase inhibitors (JAKis) more effective among elderly patients with RA, smokers and those with higher cardiovascular risk? A comparative effectiveness study of b/tsDMARDs in Sweden
Authors' conclusion
As used in clinical practice, response and remission at 6 months with JAKis are higher than with TNFi. Among patients with risk factors of concern, effectiveness is similar or numerically further increased.
Study context
- Population
- Individuals with RA starting b/tsDMARDs in Sweden 2016–2022, all lines of therapy (majority second line or higher)13,493 individuals
- Participants
- 3,166 / 5,575 / 11,286
- Comparison
- JAKi, and non-TNFi, vs tumour necrosis factor inhibitors (TNFi) in RA, overall and by cardiovascular (CV) risk, age, sex and smoking
- JAKin = 3,166
- Non-TNFin = 5,575
- TNFin = 11,286reference
- Outcome
- Proportion reaching EULAR good response and CDAI remission, respectively
- Follow-up
- Within 6 months
Methodological detailsSwedish registers, linear regression models adjusted for confounders, adjusted Poisson models
- Swedish registers
- Linear regression models adjusted for confounders
- Adjusted Poisson models
Main finding
As reported in the abstract
EULAR good response and CDAI remission within 6 months, overall and by risk factor
Adjusted percentage point difference
- EULAR good response, overall
- +5.0% (95% CI 2.2%–7.9%)
- Clinical Disease Activity Index (CDAI) remission, overall
- +5.8% (95% CI 3.2%–8.5%)
- EULAR good response, age >65
- +5.9% (95% CI 2.7%–9.0%)
- EULAR good response, elevated CV risk
- +8.3% (95% CI 5.3%–11.4%)
- EULAR good response, smokers
- +6.0% (95% CI 3.3%–8.7%)
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Are JAKis more effective among elderly patients with RA, smokers and those with higher cardiovascular risk? A comparative effectiveness study of b/tsDMARDs in Sweden. RMD Open. Published 26 December 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →